Olutasidenib for IDH1-mutated blood cancers after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with AML, MDS, or CMML that has an IDH1 mutation.
- You have had or are scheduled to have a donor stem cell transplant (allogeneic HCT).
- Your blood counts (ANC, hemoglobin, platelets) are within certain levels before starting the study drug.
- Your liver and kidney function tests are acceptable.
- You do not have a serious active infection or other cancer that is not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial studies a new drug called olutasidenib for people with certain blood cancers (acute myeloid leukemia or myelodysplastic syndromes) that have a specific genetic change (IDH1 mutation). The drug may be used alone or with other treatments, depending on the type of blood cancer.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.